Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?
FDA Staff Cuts Are Already Impacting Regulatory Work, Biotech Leaders Warn
PepGen Inc.'s CEO Makes Bold Stock Purchase!
Insider Purchase: President and CEO of $PEPG Buys 41,500 Shares
Express News | PepGen Announces Appointment of Two New Directors to Its Board
PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
PepGen Pauses Phase II DMD Trial to Review Safety Data
PepGen to Pause Study in Duchenne Muscular Dystrophy; Shares Down Pre-Bell
PepGen to Participate in Upcoming Investor Conferences
Express News | PepGen Inc - No New Safety Issues Observed in Pgn-Edo51 Program
Express News | PepGen Inc - Data From 10 Mg/Kg Cohort Expected in Q3 2025
Express News | PepGen Announces Update to Phase 2 Connect2-Edo51 Study in Patients With Dmd
Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?
$PEPG Stock Is up 9% Today. Here's What We See in Our Data.
PepGen (PEPG) Shares Rally In Extended Session
Promising Prospects for PepGen Inc.: Buy Rating Affirmed Amid Positive DM1 Treatment Developments
PepGen Inc. Reports Positive Trial Results and Financials
What's Driving the Market Sentiment Around PepGen?
PepGen Reports Positive Initial Data From Phase I DM1 Therapy Trial
H.C. Wainwright Maintains PepGen(PEPG.US) With Buy Rating, Maintains Target Price $16